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Abstract
For metastasis to occur cells must communicate with to their local environment to initiate
growth and invasion. Exosomes have emerged as an important mediator of cell-to-cell sig-
nalling through the transfer of molecules such as mRNAs, microRNAs, and proteins be-
tween cells. Exosomes have been proposed to act as regulators of cancer progression.
Here, we study the effect of exosomes on cell migration, an important step in metastasis.
We performed cell migration assays, endocytosis assays, and exosome proteomic profiling
on exosomes released from three breast cancer cell lines that model progressive stages of
metastasis. Results from these experiments suggest: (1) exosomes promote cell migration
and (2) the signal is stronger from exosomes isolated from cells with higher metastatic po-
tentials; (3) exosomes are endocytosed at the same rate regardless of the cell type; (4) exo-
somes released from cells show differential enrichment of proteins with unique protein
signatures of both identity and abundance. We conclude that breast cancer cells of increas-
ing metastatic potential secrete exosomes with distinct protein signatures that proportionally
increase cell movement and suggest that released exosomes could play an active role
in metastasis.
INTRODUCTION
Exosomes are small membrane vesicles (30–100nm) derived from the luminal membranes of
multivesicular bodies (MVB) and are released from mammalian cells by exocytosis [1–5].
Along with diffusible signals, such as cytokines, growth factors, and proteases, exosomes medi-
ate short- and long-range cell-to-cell communication by transferring proteins, RNA, and lipids
between cells [5–9]. Exosome release occurs under normal physiological conditions and abnor-
mal release of exosomes can arise in diseases such as cancer. The magnitude of exosome release
has been linked to tumor invasiveness both in vitro and in vivo [10,11]. Exosomes are small
enough to penetrate into and interact with tissues, and have been shown to promote increased
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migration and proliferation of tumors [12–14]. Exosomes have also been shown to affect
unique stages of tumor progression, including angiogenesis, escape from immune surveillance,
extracellular matrix degradation, and metastasis [15–20].
For metastasis to occur, a cell must manipulate its local environment to optimize invasion
and growth [21–23]. The molecular steps of metastasis can be divided into 3 stages: (1) loss of
adhesion; (2) increased migration; and (3) increased invasion. The metastatic potential of can-
cer cells is a term given to cancers to classify the level of phenotypic changes that are linked to
increased metastatic behaviors [24]. For example, a high metastatic potential correlates with
high rates of migration and motility. A subset of specific genes that regulate the tumor micro-
environment are positively linked to the increased invasiveness (increased metastatic poten-
tial) of the cancer [24–28]. Thus, this classification can be gained from several experimental
methods including microarray analysis, gene-expression profiling, and proteomics. A similar
signature has been suggested for other signaling components of cancers, including exosomes
[29–34].
Here, we examined the effects of exosomes on cell migration, a key step in metastasis. We
show that exosomes stimulate cell migration. Furthermore, we show that exosomes induce mi-
gration proportional to the metastatic potential of the cell from which the exosomes originated.
We then identified and quantified the proteins associated with these exosomes. From this
work, we provide the first comprehensive proteomic catalog of exosomes isolated from breast
cancers cells of increasing metastatic potentials. Our results support the idea that exosomes are
a positive signal for cell motility and growth. This signal is stronger in exosomes from cells
with higher metastatic potentials [35]. Our work suggests a role for exosomes in accelerating
cancer progression and identifies new biomarkers that could be used as therapeutic targets or
indicators of metastasis.
RESULTS
To examine the role of released exosomes on cell motility, we first isolated exosomes from cul-
tured cells that represent different metastatic potentials. We chose MCF-7 and MDA-MB-231
cells, two commonly used breast cancer cell lines [26,36]. MCF-7 cells are tumorigenic but
non-metastatic and represent the lowest metastatic potential in this study. MDA-MB-231 cells
are highly metastatic, with altered adhesion and motility properties and thus have the highest
metastatic potential in this study. To develop a model cell line with intermediate metastatic po-
tential we created an MCF-7 cell line that stably over-expresses GFP-tagged Rab27b. Increased
expression of Rab27b has been shown to promote G1 to S phase cell cycle transition, prolifera-
tion, and invasiveness of cells in culture. Rab27b also has been shown to promote invasive
tumor growth in mouse xenograph models. When we plated MCF-7 cells that overexpress
GFP-Rab27b on type I collagen coverslips, we observe four distinct changes in these cells.
1) They exhibited a more extended morphology characteristic of more metastatic cells. 2) They
showed increased motility. 3) Rab27b-GFP exhibited cell peripheral localization (Fig. 1A-B),
and 4) the cells exhibited a (~3-fold) increase in cell proliferation over control cells transfected
with GFP at limiting (0.5%) serum concentrations (Fig. 1C) in agreement with previous work
[37]. Rab27b levels were additionally determined in the three cell lines (MCF-7; Rab27b/MCF-
7; and MDA-MB-231) by western blotting (Fig. 1F). Thus, MCF-7 cells that stably overexpress
Rab27b (referred to as Rab27b cells) represent a tumorigenic and transformed line of moderate
metastatic potential in this study. The levels of metastasis associated with each breast cancer
cell line was further confirmed and validated with a matrigel cell invasion assay (Fig. 1D-E).
Exosomes purified from these three cells by serial ultra-centrifugation [38] were observed
by transmission electron microscopy to be small (50–120nm) spherical vesicles (Fig. 2A-B). To
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ensure that we isolated exosomes from our preparations, we conducted Western blotting to
confirm the presence of several common exosome/vesicle markers, including TSG101, ALIX,
HSP70, HSP90 (Fig. 2C). The presence of these markers is consistent with purified exosome
samples. Additionally, we further analyzed (in triplicate) our exosome preparations using
Fig 1. Characterization of invasiveness associated with non-metastatic andmetastatic breast cancer cell lines. (A) Punctate expression pattern and
cellular extensions of MCF-7 cells stably transfected with GFP-Rab27b-expressing plasmids. (B) Cells overexpression GFP-Rab27b formed cellular
extensions with peripherally-localized GFP-Rab27b, and a spreading morphology on collagen-coated coverslips. (C) Measurement of cell proliferation of
MCF-7 cells stably expression GFP or GFP-Rab27b. The same number of cells was plated in triplicate into 10 cm dishes on day 1 and the total number of
cells was counted on day 8. (D) Matrigel invasion assay with MCF-7 GFP, MCF-7 Rab27b GFP, and MDA-MB-231cells. 105 cells were seeded in serum free
media on a Matrigel-coated filter and their migration toward medium containing serum was quantified by microscopic evaluation. MCF-7 cells stably
overexpressing GFP-Rab27b showed significant increased invasion into matrigel compared to MCF-7 GFP cells (mean = 55.7 vs. 14.7 cells, P<0.0001). The
well-characterized invasive MDA-MB-231 cell line showed massive invasion into matrigel, which has been described previously [62]. (E) The mean total
number of invading cells from 10 different fields is shown P values were calculated using two-sided Student t tests. Statistically significant P values are
indicated (n = 3); (F) Western blot analysis of protein extracts fromMCF-7, MDA-MB-231, MCF-7 /GFP, MCF-7/GFP-RAB27a, and MCF-7/GFP-RAB27b
probed with antibodies to GFP, RAB27a, and RAB27b. An anti-HRP conjugated β-actin antibody was used as a protein loading control. The established
MCF-7 RAB27b GFP cell line showed over-expression of GFP-RAB27b demonstrated with an anti-GFP antibody, RAB27b antibody, and RAB27a antibody.
Lysates of previously described cell lines (MCF-7 GFP, MCF-7 RAB27a GFP) were included as controls to show specificity of the antibodies [37].
doi:10.1371/journal.pone.0117495.g001
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nanoparticle tracking analysis (NTA) which measures particles (eg. microvesicles). Based on
these measurements and the shoulder associated with the major distribution peak (Figure A-C
in S1 Fig.), it is likely that our exosome preparations isolated fromMDA-MB-231 (and to a
lesser extent also for MCF-7/Rab27b) contain a heterogeneous mixture of exosome and micro-
vesicles consistent with other high speed ultracentrifugation protocols [39]. This finding is con-
sistent with the work which suggested that several diverse population of vesicles (including
exosomes, microvesicles, ectosomes, membrane particles, exosome-like vesicles, and apoptotic
vesicles) are present in many exosome preparations obtained by differential ultracentrifugation
[39,40]. To test the effect of these vesicles on cell motility, we added the same concentration of
exosomes isolated from the three different “donor” breast cancer cells types (MCF-7, Rab27b,
MDA-MB-231) to “recipient” cells of the same or different identity from which the exosomes
were originally derived. Migration was measured in a standard wound healing assay. In this
assay, cells were plated into two zones with a space separating each population. The decrease in
the wound caused by the migration of cells over time was then quantified (Fig. 3). We observe
a substantial and reproducible wound closure (or increase in cell motility) in cells incubated
with exosomes isolated from all three donor cancer cell types compared to cells incubated in
control media (Serum-free media (SFM), with PBS only). Exosomes isolated from the moder-
ate and highly metastatic cells (Rab27b and MDA-MB-231) induced increases in cell migration
in all three recipient cell lines (Fig. 3B, D, E). Interestingly, exosomes isolated from the cells
with the highest metastatic potential (MDA-MB-231) induced the largest increase in motility,
followed by Rab27b cell line (Fig. 3C-F). The effect on cell migration induced by the exosomes
purified from the non-metastatic MCF-7 cells was modest compared to controls (Fig. 3A-B).
These data show that the effect of exosomes on migration is linked to the underlying metastatic
potential of the donor cells. Interestingly, exosomes from highly metastatic cells induced mi-
gration to a degree that depended on the metastatic potential of the donor cancer cell type. In
short, exosomes derived from the donor metastatic lines (Rab27b and MDA-MB-231) promot-
ed cell mobility faster and/or to a further extent than exosomes isolated from the non-metastat-
ic cell line (MCF-7) or control media. The migration phenotype in the moderate metastatic
line (Rab27b) occurred faster than the non-metastatic line (MCF-7) and the MDA-MB-231
cells healed the fastest overall.
Fig 2. Characterization of exosomes. (A) Large-field view of electron micrograph of exosomes released
from the human breast cancer cell line MCF-7 and stained with uranyl acetate. Scale bar, 100nm;
(B) Magnified view of electron micrograph of exosomes released from the human breast cancer cell line
MCF-7. Scale bars are 100nm. (C) Western blot analysis of exosomal proteins extracted fromMCF-7, MCF-
7/Rab27b, and MDA-MB-231.
doi:10.1371/journal.pone.0117495.g002
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Because our data suggests that the uptake of exosomes enhances cell migration, we next
asked if the effect of exosomes was due to a differential rate of endocytosis of the exosomes by
the recipient cells. To monitor endocytosis of exosomes, recipient cells were exposed to fluores-
cently-labeled exosomes derived from the same donor cell types, followed by extensive PBS
and acid washing to remove extracellular membrane bound exosomes. The increase in cytosol-
ic fluorescence which relates to the quantity of exocytosis taken up by the recipient cells was
monitored with epi-fluorescence during the treatment [41]. The rate of exosome uptake
(Fig. 4A) was calculated by determining the average fluorescence intensity in the cytoplasm as
a function of time. In these experiments, small fluorescent puncta were clearly visible inside
cells within 5 minutes of exposure and more than 50% maximal fluorescent uptake occurred
after 3 hours of exposure. The fluorescence intensity reached a maximum by 8 hours,
Fig 3. Tumor-derived exosomes increase breast cell motility. (A) Time course of cell migration wound-healing assays using MCF-7 breast cancer cells
as the “recipient” cell line with the three “donor” exosome preparations. Serum-free media was used as a control. Each point on the assay represents three
independent experiments at 21 hours. (B) Representative images from the wound healing experiments. Quantification (C) and images (D) of wound-healing
assay for MCF7/Rab27b cells in the presence of the three exosome preparations and serum-free media after 19 hours. Quantification (C) and images (D) of
wound-healing assay for MDA-MB-231 cells in the presence of the three exosome preparations and serum-free media after 15 hours. Errors were calculated
from wound closure at each time point and normalized to the wound closure at the initial time point (0 hour). Experiments were repeated two additional times
to verify results.
doi:10.1371/journal.pone.0117495.g003
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suggesting that exosome uptake had saturated (Fig. 4A inset). The subcellular distribution of
exosomes was further studied by colocalization with the lysosomal marker LAMP1 (lysosomal-
associated membrane protein 1). Colocalization of LAMP1-GFP and TAMRA-labeled exo-
somes indicated that some of the exosomes were sorted to lysosomes (Fig. 4B). In all three cell
lines, however, endocytosis of exosomes showed little difference in overall quantity or rate.
From these data we conclude that the differences in motility effect of exosomes derived from
donor cancer cells on target cells is not due to differences in the rate of endocytosis but instead
is likely related to the distinct molecular composition of the exosomes.
Because we found that exosomes from highly metastatic cells induce greater motility, we
next identified the exosomal proteome from the three different donor cancer cell types. The
proteins associated with tumor-derived exosomes were identified by nano-LC-MS analysis of
peptides obtained by in-gel digestion of SDS-PAGE gel bands. We identified a total of 513 dis-
tinct proteins in the MCF-7 cell exosomes [42] (S1 Table). As expected, many membrane-
associated proteins were identified as well as many proteins associated with other diverse cellu-
lar locations (Fig. 5A) and functions (Fig. 5B). Analysis of the subcellular localization of the
identified proteins suggested that the largest class was cytosolic proteins (37.5%). Significant
portions were integral and peripheral membrane proteins (19.8%), proteins known to be locat-
ed extracellularly (17.5%). A smaller fraction of endosomal/lysosomal proteins (3.9%) and pro-
teins assigned to the Golgi apparatus, ER, or mitochondria (other organelles; 7.2%) were
identified. The smallest fraction was nuclear proteins (4.3%). To obtain a functional overview
of the exosomal protein compositions, we annotated our proteomics into functional categories
(Fig. 5B). A total 491 of the 513 proteins identified could be assigned to defined molecular
functions. Protein binding (22%) was significantly represented in MCF-7 cell-derived exo-
somes, followed by an abundant fraction of proteins with hydrolase activity (15%). The re-
maining proteins were distributed over several general groups including structural proteins
(~6%), ion binding proteins (~6%), oxidoreductases (~4%), transferases (~6%), enzyme
Fig 4. Endocytosis of exosomes in breast cancer cells. (A) Time-course curve of exosome uptake
(endocytosis) by determining fluorescent intensity of TAMRA-labeled exosomes from “donor” cancer cells at
specific times. Inset shows a MCF-7 “recipient” cells incubated with TAMRA-labeled MCF-7 “donor”
exosomes at 8 hours. Errors were calculated from fluorescence intensity of cells (n = 50), at each time point,
normalized to the intensity at the final time point (24 hours). (B) Colocalization of TAMRA-labeled exosomes
added to MCF-7 cells transiently transfected with LAMP1-GFP. Scale bar is 10μm.
doi:10.1371/journal.pone.0117495.g004
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regulators (~4%), and molecular transducers (~5%). These data suggest that the tumor-derived
exosomes contain proteins with extremely diverse functions and cellular origins.
The function of exosomes is dependent on the cargo they carry, which is dependent on the
cell type they were derived [43]. Thus, differences in expression of specific exosomal proteins
could be related to the increases in migration induced by metastatic cell-derived exosomes
(Rab27b and MDA-MB-231). Next, we quantified the relative amount and identity of exosomal
proteins from our breast carcinoma cell lines [24] and performed iTRAQ-based quantitative
proteomic analysis. Exosomal proteins were digested, labeled, and analyzed using LC-MS/MS.
Fig 5. Cytolocalization, molecular function, and the relative abundance of proteins identified in tumor-derived exosomes. (A) Cellular localization of
exosome proteins. Relative subcellular distribution of proteins identified in the exosomes isolated from the breast cancer cell line, MCF-7. Classification of the
subcellular location of the proteins was based on the information provided by the UniProtKB/SwissProt database. (B) GO annotation of tumor-derived
proteins. Proteins identified were allocated to different molecular function categories defined by the GO consortium. Relative protein levels of exosomes
isolated fromMCF-7 are indicated by the bars. Two independent biological replicates from the breast cancer cells type, MCF-7 were used for MS analysis.
(C) iTRAQ analysis: Differential expression profile for metastatic tumor-derived exosome proteins in MDA-MB-231 and Rab27b-transformed MCF-7 cells
compared to non-invasive breast cancer cells (MCF-7). Filled and open bars represent fold change in protein expression in Rab27b and MDA-MB-231
compared to MCF-7, respectively. Two independent biological replicates from the 3 cells types (MCF-7; Rab27b; MDA-MB-231) were used for iTRAQ
analysis. The raw data give absolute expression levels of the various proteins (identity) and proteins levels (abundance) in all 3 cells lines. The average of
proteins from the two independent samples from Rab27b and MDA-MB-231 lines was determined and compared to that the average of two samples from
MCF-7 and the ratio for differential expression was determined.
doi:10.1371/journal.pone.0117495.g005
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We accepted protein identities based on at least 2 peptides with a probability higher than 95%
and minimal total protein identification probability of 99%. This yielded the identification of
1,312 proteins (S2 Table). To compare the proteome of exosomes from the three donor breast
cancer cell lines, iTRAQ-labeled peptides from all three tumor-derived exosomes preparations
were quantified [44]. Two biological replicates for each sample were included for reproducibili-
ty. After manual inspection of quantified peptides, differently expressed proteins were identi-
fied. Fig. 5C shows the proteins that were differentially expressed and their relative levels
compared to MCF-7 cells. This analysis identified 85 differentially expressed proteins (~2-fold
increase or decrease in relative expression compared to protein expression in MCF-F cells)
across the three cell lines. Surprisingly, we observed that the exosomes from the Rab27b cell
line show the same expression trends as MDA-MB-231 cells. Specifically, the levels the Rab27b
cell line exosomes varied from protein to protein but were in general less abundant than those
in the MDA-MB-231 exosomes. The overall expression signature, however, of the Rab27b exo-
somes shows a similar profile to the MDA-MB-231 exosomes (Fig. 5C). Of the 38 up-regulated
proteins, 30 proteins (79%) have been shown to be involved in metastasis and invasion. The
overexpression of these 30 proteins has been shown to be correlated with accelerated tumor
growth, invasion, and poor prognosis, and poor outcome in patients [24,26,27].
DISCUSSION
Metastasis requires breaking of cell-to-cell and cell-to-matrix interactions. This allows cells to
acquire a mobile phenotype [10,11,45]. In this study, we examined the role of exosomes in can-
cer cell motility and the progression towards metastasis. We tested the effects of exosomes
from cells of varying invasiveness on cell migration. In migration assays, we show that the abili-
ty of exosomes to promote motility correlated with the metastatic potential of the cells which
released the exosomes. We further tested whether increases in migration induced by exosomes
were the result of changes in endocytosis of exosomes. Endocytosis assays showed no differ-
ences in exosome uptake.
The level of migration is likely due to the molecular composition of exosomes. Proteomic
iTRAQ analysis of tumor-derived exosomal proteins allowed us to compare the expression of
exosomal proteins from these three breast cancer cell lines. Our data provides a “metastatic sig-
nature” of these cells. 85 Differentially expressed proteins (~2-fold increase or decrease in relative
expression) across the three breast cancer cell lines were found. Analysis of tumor-derived exo-
somes from the non-invasive breast cancer cell line MCF-7 revealed many up-regulated proteins
commonly found in exosome preparations. Some of these proteins have known tumor suppres-
sor function (Fig. 6). The catalogue of differentially enriched proteins in MCF-7-
derived exosomes can be clustered into 9 structural/functional categories. The clusters obtained
are: (1) tetraspanins; (2) adhesions; (3) calcium binding proteins; (4) cell surface receptors;
(5) transporters; (6) small GTPase superfamily; (7) endosomal trafficking; (8) stress response
proteins; and (9) vesicle budding. The remaining exosomal proteins (38/85 total; 45%) were iden-
tified as up-regulated more than 2-fold in the MDA-MB-231 and Rab27b cells. We observed a
strong trend in expression patterns from these exosomes. In both lines, we observed significantly
enriched populations of proteins with known functions in tumorigenesis and metastasis (Fig. 6).
Our results collectively identify the proteins and expression levels of exosomal proteins re-
leased from breast cancer cells under normal growth conditions. During metastasis, secreted
proteins in the extracellular space are major factors in cell invasion, migration, motility, growth
control, angiogenesis, matrix-degradation and adhesion [21]. An invasive role of tumor-
derived exosomes has also been shown by work from Higginbotham et. al which identified exo-
somes derived from cells stably expressing amphiregulin, an epidermal growth factor family
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Fig 6. Schematic representation of exosome composition and differentially expressed tumor-derived proteins. (A) Cartoon of exosome with
categories of identified associated proteins. (B) Table of differentially expressed proteins isolated from tumor-derived exosomes (MCF-7; Rab27b
transformedMCF-7; MDA-MB-231) determined by iTRAQ analysis. The average ratio (2 fold) of differentially expressed exosomal proteins across MDA-
MB-231/MCF-7 and Rab27b/MCF-7 were calculated and listed in the table.
doi:10.1371/journal.pone.0117495.g006
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member, increased invasiveness of “recipient” breast cancer cells by five-fold [46]. Of the 85
differentially expressed proteins identified, 38 of them were up-regulated in MDA-MB-231
cells. More importantly, 30 of the 38 total (79%) up-regulated invasive exosomal proteins are
also identified as potential cancer markers as overexpression of these identified proteins in can-
cer correlates with accelerated tumor growth, invasion, poor prognosis, and poor outcome in
patients [24,26,27]. While we are unable to identify the specific molecules responsible for this
effect, this approach should allow for targeted investigation of the proteins specifically up-regu-
lated in these exosomes.
For example, we identified several members of the tetraspanins family (Tetraspanin-14,
CD9, CD63, and CD81 antigens) to be increased in tumor-derived exosomes from the non-
invasive cell line, MCF-7. Tetraspanins are implicated in a diverse range of biological phenome-
na, including cell motility, metastasis, cell proliferation and differentiation and are known to
complex with integrins [47] [48,49]. Consistent with our iTRAQ analysis on tumor-derived
exosomes, members of the tetraspanin superfamily of proteins are down-regulated in metastatic
tumors, reduced [50] metastasis in vivo, and decrease cell migration [51–55]. Tetraspanin pro-
teins involved in integrin-mediated cell adhesion at the plasma membrane and could control
cell migration by regulating the connection between the cell and the extracellular matrix [56].
Many differentially expressed proteins in the exosomes belonged to the cluster of adhesion
proteins. Unlike tetraspanins, these proteins show an increased expression pattern in metastat-
ic exosomes. Extracellular matrix adhesion is critical in cancer biology and integrins are key
components mediating this adhesion [55]. In the more metastatic tumor-derived exosomes, we
observed up-regulation of unique set of adhesion proteins. These adhesion proteins induce
changes in cell shape, motility, and adhesion. Adhesion molecules act as both positive and neg-
ative modulators of the metastatic process [57]. These various regulators of adhesion in the
cells are represented in the composition of adhesion proteins in tumor-derived exosomes from
breast cancer cells of varying invasiveness.
We show that there are a relatively small number of proteins that are differentially expressed
in exosomes from all three breast cancer cell lines. Many of these proteins have been shown to
have known functions in migration. A similar observation was made by difference, microarray,
and proteomics analysis of breast cancer cells of varying invasiveness [26]. Their finding
showed that a small subset of proteins may serve as an accurate signature of metastasis. We
propose that there is likewise a unique pattern of expressed proteins contained in tumor-
derived exosomes. This signature can be used to define the metastatic potential of the cell that
released the exosomes. Further studies will be required to determine if these proteins are
therapeutic targets.
METHODS
Constructs and transfections
EGFP-Rab27b plasmid was kindly provided by Dr. WendyWestbroek (NHGRI, NIH, Be-
thesda, USA). Breast cancer cell lines MCF-7 and MDA-MB-231 were stably or transiently
transfected using Lipofectamine 2000 (Invitrogen). To establish stable cell lines, singly trans-
fected cells were selected in G418 (1mg/ml) (Invitrogen) for>4 weeks.
Cell culture
The non-invasive/non-metastatic breast cancer cell line, MCF-7 and invasive/metastatic breast
cancer cell line, MDA-MB-231 (ATCC) was cultured in Dulbecco’s modified eagles medium
(DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals), 100U/
ml penicillin, and 100μg/ml streptomycin, in a 5% CO2 humidified atmosphere at 37°C. For
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exosome purification, cells were cultured until ~90% confluency (~7–8 days) with DMEM and
FBS deprived of bovine microvesicles by ultracentrifugation (4 hours at 200,000 x g). Cells were
plated onto collagen-coated coverslips.
Isolation tumor-derived exosomes
Exosomes were purified by differential centrifugation as previously described with slight modi-
fications to the ultracentrifugation speeds and times [38],[41,58]. Briefly, culture medium con-
taining exosome-free FBS from cells were collected after ~90% confluency, filtered by 0.22μm
syringe filter to exclude cell debris, ultrafiltrated and condensed through Amico Ultra-15 cen-
trifugal (Millipore) concentrators. The condensed culture medium was centrifuged at 2,000 x g
for 10 minutes, followed by 21,000 x g for 30 minutes using a type SS-34 rotor in a Sorvall Evo-
lution RC centrifuge (Beckman Coulter, USA), and then 200,000 x g for 2 hours using a type 70
Ti rotor in a Beckman Coulter Optima L-100 XP utracentrifuge (Beckman Coulter, USA) to re-
move exosomes further. The exosome pellet was resuspended in PBS.
Fluorescent labeling of exosomes
For labeling exosome proteins, 500μg exosome protein was added to 1ml 0.1M sodium bicar-
bonate buffer (pH ~8.3) containing 100μg TAMRA-NHS (carboxytetramethylrhodaminesucci-
nimidyl ester, Biotium). Reactions were performed for 1 hour at room temperature. The
unincorporated TAMRA-NHS was removed by using a 100kDa ultrafiltration tube (Millipore)
and ten 30 minutes extended washing in PBS before concentrate was collected and washed
once in PBS with 200,000 x g centrifugation for 1 hour. The concentrated solution was collect-
ed, diluted to 200μl in PBS, and used directly for exosome uptake assays. For the purposes of
removing unincorporated TAMRA, we compared purification of TAMRA-labeled exosomes
using ultrafiltration (100kDA ultrafiltration tube (Millipore)), dialysis (10kDa slide-a-lyzer Di-
alysis Cassettes) and PD-10 desalting column. All the purifications work equally well and give
similar results for exosome uptake assays (data not shown).
Electron microscopy
Five microliters aliquots of resuspended exosomes were placed onto support grids (Cu 200M),
and allowed to absorb for 60 seconds. Grids were washed twice in double distilled water and
vesicles were then stained for 10 sec in 2% uranyl acetate. The size and morphology of the par-
ticles were examined using a transmission electron microscope.
Exosome uptake assay
Fluorescently labeled, TAMRA-exosomes (10–50μlu derived from breast cancer cells (MCF-7;
Rab27b; MDA-MB-231) were added to recipient cells and monitored using EPI fluorescence.
Excessive exosomes were washed by culture media at various time intervals. To quantify the
cellular uptake of exosomes and for each experiment more than 50 cells were imaged. All the
settings of imaging and processing were kept constant and the relative fluorescent intensities
were calculated.
Wound healing assay
MCF-7, Rab27b-transformed MCF-7, or MDA-MB-231 breast cancer cells were plated on col-
lagen coverslips, into culture inserts (Idibi) specially made for wound healing assays. Wound
healing assay were performed as previously described [59,60]. Briefly, attached cells were
washed twice with 1x PBS and serum-free media (SFM) was used to cover each coverslip along
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with control, PBS, or 50μg exosomes isolated from the three breast cancer cell lines. Pictures
were taken immediately after wound closure (15–21 hours depending on cell types).
Confocal microscopy
Images were captured with a Zeiss LSM 510 confocal microscope with 488nm and 561nm la-
sers and a 63x objective lens. Filters used were 500–530 nm (EGFP) and 550–650nm
(mCherry).
Proteomics/Liquid Chromatography-Coupled TandemMass
Spectrometry
Eluted proteins were reduced and alkylated in solution using iodoacetamide, and proteolyzed
with sequencing grade modified porcine trypsin (Promega, Madison, WI). Protein
identification by LC-MS/MS analysis of peptides was performed with an LTQ ion trap MS
(Thermo Fisher Scientific, San Jose, CA) interfaced with a 2D nanoLC system (Eksigent,
Dublin, CA). Peptides were fractionated by reverse-phase HPLC on a 75 μm×100 mm C18
column with a 10 μm emitter using a 0–60% acetonitrile/0.5% formic acid gradient over
30 min at 300 nl/min. Peptide sequences were identified using Mascot software (version 2.2,
Matrix Science, Boston, MA) to search the NCBI non-redundant database with the acquired
fragmentation data. Identified sequences were confirmed manually by inspecting the frag-
mentation spectra. Scaffold (version Scaffold_2_04_00, Proteome Software Inc., Portland,
OR) was used to validate MS/MS based peptide and protein identifications. Peptide identifi-
cations were accepted if they could be established at greater than 95% probability as specified
by the Peptide Prophet algorithm embedded within Scaffold. Low probability enabled poten-
tially significant protein identifications based on many moderate-probability peptides, but no
such proteins emerged; instead nearly all identifications were based on peptides with individ-
ual confidences>80%. Protein identifications were accepted if they could be established at
greater than 89% probability based on at least 1 identified peptide. Protein probabilities were
assigned by the embedded Protein Prophet algorithm. Proteins that contained similar pep-
tides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy
the principles of parsimony.
iTRAQQuantitative proteomics
Exosomes were lysed in lysis buffer (2% SDS, 1% Triton-X100, 0.1M Tris pH 7.4, 1 tablet Com-
plete EDTA-free protease inhibitors (Roche, Indianapolis, IN, USA) and concentrations were
determined using BSA protein assay (Pierce, Rockford, IL, USA)). Exosome samples derived
fromMCF-7, Rab27b, MDA-MB-231 breast cancer cells (100μg each) were labeled with
iTRAQ (isobaric tagging for relative and absolute quantification) reagents (Life Technologies),
purified and fractionated with strong cation exchange chromatography (SCX) and analyzed on
a VelosOrbitrap mass spectrometer. After proteins were precipitated, samples were mixed with
6 volumes of cold acetone and incubated for 60 min at -20°C. After 10 min of centrifugation at
13,000x g at 4°C, the supernatant was removed and the rest of the acetone was allowed to evap-
orate from the uncapped tubes at room temperature. Next, proteins were digested by reconsti-
tuting protein pellets with 20:l of dissolution buffer (0.5M triethylammonium bicarbonate), 1:l
denaturant (2% SDS), and 2:l reducing reagent [50mM tris-(2-carboxyethyl) phosphine]. The
sample were mixed by vortexing, spun down and incubated at 60°C for 1 hour. Free cysteines
were blocked by adding 1:l of 200μMmethyl methanethiosulfonate in isopropanol and incu-
bated for 10 min at room temperature. Trypsin (Promega) was reconstituted with deionized
water at 1μg/μl concentration. Trypsin (10μl) solution was added to each vial and incubated
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overnight at 37°C followed by iTRAQ labeling. 8-Plex iTRAQ reagents were allowed to reach
room temperature and then reconstituted with 50ml of isopropanol. Each label reagent was
mixed with the corresponding protein digest and incubated at room temperature for 2 hours.
Samples were pooled into a new vial and dried using a centrifugal evaporator (Speedvac). After
reconstituted with 0.1% formic acid (FA), the digest was desalted on an Oasis HLB 1 cc column
(Waters, Milford, MA, USA) and eluted with 60% acetonitrile (ACN) 0.1% FA. Eluted peptide
mixtures were dried by centrifugation evaporation, reconstituted with 100μl SCX buffer A
(10mM KH2PO4, 20% ACN, pH 2.7) and separated on a PolyLCPolySULFOETHYL A column
(200x 2.1 m, 5 mm, 200 Å) with a linear 200μl/min gradient of 0–70% buffer B (10mM
KH2PO4, 20% ACN, 500mMKCl, pH 2.7) in 45 min on an Agilent 1200 LC device with Chem-
station B.02.01 control software (Agilent, Santa Clara, CA, USA). Fractions were collected each
minute and eventually pooled into 24 fractions. After vacuum centrifugation to evaporate the
solute, fractions were desalted, eluted, dried as described above and reconstituted with 0.1%
FA. Liquid chromatography was performed on an Eksigent nanoLC-Ultra 1D plus system
(Eksigent, Dublin, CA, USA). Peptide digest was first loaded on a Zorbax 300SB-C18 trap (Agi-
lent) at 6μl/min for 5 min, then separated on a PicoFrit analytical column (100mm long, ID
75μm, tip ID 10μm, packed with BetaBasic 5μm 300 Å particles; New Objective, Woburn, MA,
USA) using a 40-min linear gradient of 5–35% ACN in 0.1% FA at a flow rate of 250 nl/min.
Mass analysis was carried out on an LTQ OrbitrapVelos (Thermo Fisher Scientific, San Jose,
CA, USA) with data-dependent analysis mode, where MS1 scanned full MS mass range from
m/z 300 to 2,000 at 30,000 mass resolution and 6 HCDMS2 scans were sequentially carried
out at resolution of 7,500 with 45% collision energy, both in the Orbitrap.
Database search and quantitative data analysis
MS/MS spectra from 24 fractions were searched against the Swiss Prot (Swiss Institute of Bio-
informatics, updated August 10, 2010, 21,241 entries) database, taxonomy Human using our 6-
processor Mascot (Matrix Science, London, UK; version 2.3) cluster at NIH (http://biospec.
nih.gov), with precursor mass tolerance at 20 ppm, fragment ion mass tolerance at 0.05 Da,
trypsin enzyme with 2 miscleavages, methyl methanethiosulfonate of cysteine and iTRAQ
8plex of lysine and the N-terminus as fixed modifications, and deamidation of asparagine and
glutamine, oxidation of methionine and iTRAQ 8plex of tyrosine as variable modifications.
The resulting data file was load into Scaffold Q_(version Scaffold_3_00_04, Proteome Software
Inc., Portland, OR, USA) to filter and quantitate peptides and proteins. Peptide identifications
were accepted at 95.0% or higher probability as specified by the Peptide Prophet algorithm and
a false discovery rate (FDR) of less than 1%. Protein identifications were accepted at 99.0% or
higher probability and contained at least 2 identified peptides with FDR less than 1%. Protein
probabilities were assigned by the Protein Prophet algorithm. Proteins that contained similar
peptides and could not be differentiated based on MS/MS analysis alone were grouped to satis-
fy the principles of parsimony. Peptides were quantitated using the centroid reporter ion peak
intensity, with minimum of 5% of the highest peak in the spectrum. Intrasample channels were
normalized based on the median ratio for each channel across all proteins. The isobaric tagged
samples were normalized by comparing the median protein ratios for the reference channel.
Quantitative protein values were derived from only uniquely assigned peptides. The proteomic
data has been submitted to the Vesiclepedia database [61], http://www.microvesicles.org/.
Western blotting
Cells were washed 3x with PBS (Life Technologies, Grand Island, NY) and scraped and lysed in
RIPA buffer containing a protease inhibitor mix (Roche Diagnostics, Indianapolis, IN). The
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lysates were sonicated, mixed with 2x Laemmli sample buffer (Bio-Rad, Hercules, CA)in a 1:1
ratio and boiled for 5 min followed by centrifugation at 5,000g for 10 min. 20 microgram of
total protein, as determined by DC protein assay (Bio-Rad), was loaded onto 4–20% Criterion
TGX precast gels (Bio-Rad). The Trans-Blot Turbo (Bio-Rad) device was used for transfer onto
PVDF membranes (Bio-Rad). Membranes were dried followed by activation in 100% methanol
and blocking in PBS (Life technologies) plus 5% milk and 0.5% Tween (Sigma, St. Louis, MO)
for 60 min. at RT. The protein containing PVDF membranes were probed overnight in PBS
with 5% milk and 0.5% Tween at 4°C with a mouse monoclonal antibody demonstrated to be
specific for Rab27A [37] (BD Biosciences, San Jose, CA), an anti-Rab27B polyclonal antibody
(Novus Biologicals, Littleton, CO), and an anti-GFP mouse monoclonal antibody (Millipore,
Billerica, MA). An anti-β-Actin-HRP (Abcam, Cambridge, MA) antibody was used as a protein
loading control. Membranes were washed 3x with PBS with 5% milk and 0.5% Tween for 5
min followed by incubation with secondary antibodies in PBS with 5% milk and 0.5% Tween at
RT for 60 min. Membranes were washed 5x in PBS with 0.5% Tween for 5 min followed by
ECL detection (Amersham Biosciences, Piscataway, NJ). For WB on purified exosomes 15 mi-
crogram of total protein was loaded; PVDF membranes were incubated with anti-Alix (Cell
Signaling, Danvers, MA), anti Tsg101 (Santa Cruz Biotechnology Inc, Dallas, TX), anti-HSP90
(Thermo Scientific, West Palm Beach, FL), and anti-HSP70 (System Biosciences, Mountain
View, CA). Secondary antibodies were HRP-conjugated secondary anti-mouse or anti-rabbit
antibodies (Amersham Biosciences, Piscataway, NJ).
Nanoparticle Tracking Analysis
The size and concentration of particles were determined via nanoparticle tracking analysis
(NTA) using a NanoSight LM10-HS instrument (NanoSight, Amesbury, UK) equipped with a
405nm laser. 5 μg protein was diluted in 1.5 ml PBS. For each condition three independent
samples were prepared and batch processed. Per measurement a movie of 60 s was recorded.
All data were analyzed with the NTA Analytical Software suite version 2.3. The NanoSight sys-
tem was calibrated with polystyrene latex microbeads (Thermo Scientific) prior to analysis.
Matrigel Invasion assay
For each cell line, 1x105 cells were seeded in transwell chambers with Matrigel-coated mem-
brane (24-well insert; pore size 8 μm; Becton Dickinson, Franklin Lakes, NJ) in serum-and an-
tibiotic-free DMEMmedium; DMEM with 10% fetal calf serum was used as chemoattractant
in the lower chamber. Cells that did not invade through the pores of the membrane were re-
moved with a cotton swab after 48 hours. The membrane was mounted on a coverslip and cells
on the lower surface of the membrane were stained with ProLog Gold antifade reagent with
DAPI (Life Technologies, Grand Island, NY). Invasive cells were counted in 10 microscopic
fields using a fluorescence microscope (Axiovert 200M; Carl Zeiss, Thornwood, NY) with a
40× objective. Statistical analyses were performed using GraphPadPrism5.0 software. Matrigel
invasion data were analyzed by using two-sided Student t tests.
Supporting Information
S1 Fig. Nanoparticle tracking analysis (NTA) of tumor-derived exosomes/microvesicles.
NTA of exosome/microvesicles derived from (A) MCF-7; (B) MCF-7/Rab27b; and (C) MDA-
MB-231. Size and particle distribution (concentration) plots of exosome samples from all three
cells lines done in independent and duplicate preparations of each cell line.
(TIF)
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S1 Table. Proteomics and iTRAQ analysis of tumor derived exosomes/microvesicles.
(1) Identification of MCF-7 tumor-derived exosomes from in-gel digestion; (2) iTRAQ analysis
of tumor-derived exosomal proteins fromMCF-7; Rab27b; and MDA-MB-231 breast cancer
cells lines.
(XLSX)
S2 Table. Proteomics and iTRAQ analysis of tumor derived exosomes/microvesicles.
(1) Identification of MCF-7 tumor-derived exosomes from in-gel digestion; (2) iTRAQ analysis
of tumor-derived exosomal proteins fromMCF-7; Rab27b; and MDA-MB-231 breast cancer
cells lines.
(XLSX)
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